01Approach to the Critical Patient/attcp36

Immediate priorities

›Airway assessment and protection

›Descending paralysis with bulbar involvement — early intubation risk

›FVC < 15 mL/kg — intubation threshold

›NIF weaker than -20 cmH2O — intubation threshold

›Inability to handle secretions or lost gag reflex

›Avoid succinylcholine for RSI

›Unpredictable response at dysfunctional neuromuscular junction

›Rocuronium preferred if neuromuscular blockade needed

›If progressive cranial nerve palsies with respiratory trend, early intubation planning

›Do not wait for complete failure

›Class I recommendation for airway protection in neuromuscular respiratory compromise

Hemodynamic and autonomic monitoring

›Monitoring targets

›Continuous pulse oximetry

›SpO2 target 94% to 98%

›Tachypnea and declining SpO2 are late signs

›Cardiac telemetry

›Autonomic dysfunction can cause sinus tachycardia or bradycardia

›Rare ventricular tachycardia reported

›Blood pressure monitoring

›Orthostatic hypotension from autonomic involvement

›Urinary retention monitoring — autonomic dysfunction feature

Immediate interventions and consults

›Time-critical actions

›Contact state health department and CDC immediately for heptavalent botulinum antitoxin (BAT)

›Available 24/7 through CDC Emergency Operations: 770-488-7100

›Earlier administration associated with significantly shorter ICU stay and ventilation duration

02History/hx45

Presentation pattern

›Core neurologic syndrome

›Symmetric descending flaccid paralysis

›Cranial nerve palsies first — diplopia, ptosis, dysarthria, dysphagia

›Proximal limb weakness following cranial involvement

›Autonomic symptoms

›Dry mouth

›Constipation and urinary retention

›Fixed or dilated pupils — though reactive pupils do not exclude diagnosis

›Absence of fever, sensory deficits, and altered mental status

›Key distinguishing triad from GBS and encephalitis

›No preceding GI illness in wound botulism — unlike foodborne type

Exposure and wound history

›Injection drug use details

›Route of injection — subcutaneous or intramuscular skin popping vs. intravenous

›Black tar heroin skin popping is the dominant risk factor in the US

›Skin popping creates low-oxygen tissue pockets favorable for C. botulinum

›Type and source of drug

›Black tar heroin especially associated with wound botulism clusters

›Shared drug supply — screen for cluster exposure

›Recent wound, abscess, or drainage procedure

›Days to weeks before symptom onset

›Incubation period typically 4 to 14 days after wound contamination

›Traumatic or surgical wounds

›Crush injury, open fracture, gunshot wound

›Devitalized anaerobic tissue enables spore germination

›Much rarer than injection drug use as cause

03Physical Exam/exam58

Vitals and general

›Stability assessment

›Temperature

›Typically afebrile in wound botulism

›Fever suggests concurrent wound infection rather than toxin effect

›Respiratory rate

›Rising rate is early respiratory decompensation signal

›Paradoxical breathing pattern — diaphragmatic fatigue

›Oxygen saturation

›Declining SpO2 is a late sign — do not wait for hypoxemia to intubate

›Heart rate

›Tachycardia may reflect autonomic dysfunction or impending respiratory failure

Cranial nerve examination

›Cranial nerve findings

›Pupils

›Fixed or dilated pupils in some cases

›Reactive pupils present in approximately 46% — do not exclude diagnosis

›Extraocular movements

›Ophthalmoplegia and diplopia

›Bilateral ptosis

›Facial

›Facial diplegia — expressionless face

›Weak jaw closure

›Bulbar function

›Dysarthria

›Dysphagia — absent or diminished gag reflex

›Pooling of secretions

04Differential Diagnosis/ddx44

Life-threatening mimics

›Guillain-Barre syndrome

›ICD-10 G61.0

›Ascending weakness pattern — opposite of botulism

›Miller Fisher variant descends and closely mimics botulism

›Elevated CSF protein — normal in botulism

›Albuminocytologic dissociation on lumbar puncture

›Myasthenia gravis

›ICD-10 G70.01

›Fatigable weakness — worsens with repetitive use

›Positive AChR or MuSK antibodies

›Postsynaptic defect — botulism is presynaptic

›Positive edrophonium test — partial or absent response in botulism

›Brainstem stroke

›ICD-10 I63.9

›Typically asymmetric cranial nerve involvement

›Abnormal brain imaging distinguishes

›Crossed findings — ipsilateral face, contralateral body

Neuromuscular junction and nerve disorders

›Lambert-Eaton myasthenic syndrome

›Proximal weakness with facilitation on repetitive stimulation

›Associated with small cell lung carcinoma

›CMAP increment on high-frequency stimulation — similar to botulism pattern

›No cranial nerve palsies as dominant feature

›Tick paralysis

›Ascending paralysis pattern

›Scalp examination for embedded tick

›Rapid resolution after tick removal

05Laboratory Tests/lt37

Confirmatory and diagnostic labs

›Botulinum toxin detection

›Serum botulinum toxin assay — mouse bioassay

›Submit through state health department or CDC

›Results in 1 to 4 days — do not delay treatment pending results

›Positive in approximately 60% to 70% of wound botulism cases

›Wound culture for Clostridium botulinum anaerobes

›Submit anaerobic culture swab from wound base

›Low yield but supportive if positive

›Must specify anaerobic culture at laboratory submission

Exclusion and baseline labs

›Routine labs for differential and baseline

›Complete blood count

›Typically normal — no leukocytosis expected from toxin alone

›Leukocytosis suggests concurrent wound infection

›Comprehensive metabolic panel

›Electrolytes — hypokalemia and hypophosphatemia worsen neuromuscular function

›Renal function for antibiotic dosing

›Liver function tests — baseline for antitoxin administration

›Cerebrospinal fluid analysis

›Normal in botulism — key differentiator

›Elevated protein suggests Guillain-Barre syndrome

›Normal cell count and glucose

›Obtain when GBS is in differential

›Autoimmune and toxicologic testing

›Acetylcholine receptor antibodies — to exclude myasthenia gravis

›MuSK antibodies — anti-muscle-specific kinase

›Urine drug screen — confirm drug use history

06Diagnostic Tests/dt77

Scoring Systems

›Botulism severity classification

›Mild — cranial nerve palsies only

›No limb weakness

›No respiratory compromise

›Moderate — cranial nerve palsies plus limb weakness

›Ambulatory or near-ambulatory

›Monitoring for respiratory progression

›Severe — respiratory failure requiring mechanical ventilation

›100% of wound botulism patients in one outbreak series required intubation

›Prolonged ICU course expected — weeks to months

›Neuromuscular respiratory failure rule of 20-30-40

›FVC < 20 mL/kg triggers urgent consideration

›NIF weaker than -30 cmH2O triggers urgent consideration

›Peak expiratory flow < 40 L/min triggers urgent consideration

›Any single criterion met — escalate to ICU monitoring

›Two or more criteria — immediate intubation planning

MRI

›MRI brain and brainstem

›Primary role — exclusion of structural brainstem pathology

›Normal in wound botulism

›Identifies pontine lesions, demyelination, or hemorrhage mimicking botulism

›Indications

›Asymmetric cranial nerve findings — atypical for botulism

›Altered mental status — not expected in botulism

›Imaging change concern prior to lumbar puncture

›Limitations

›Time and access constraints in critically ill patients

›MRI does not confirm botulism — diagnostic only by exclusion

›MRI spine

›Consider when ascending paralysis pattern present

›Cervical cord lesion exclusion

›Transverse myelitis mimic

CT

›CT brain

›Normal in wound botulism

›Used to exclude brainstem stroke or mass lesion

›Faster than MRI in unstable patients

›Obtain when

›Asymmetric neurologic findings

›Altered consciousness not explained by botulism

›Prior to lumbar puncture when mass lesion concern

›CT soft tissue of wound or extremity

›Indications

›Abscess, gas collection, or necrotizing soft tissue infection

›Surgical planning for debridement

›CT findings suggesting anaerobic infection

›Gas in soft tissue planes — subcutaneous emphysema

›Poorly defined deep abscess cavity

›Fascial plane involvement

›CT chest

›Baseline aspiration risk assessment

›Aspiration pneumonia is common complication in intubated patients

›Atelectasis from poor respiratory effort

Ultrasound

›Wound and soft tissue ultrasound

›Abscess identification at injection sites

›Hypoechoic fluid collection with posterior acoustic enhancement

›Guides drainage or surgical planning

›POCUS advantage over CT

›No radiation, immediate at bedside

›Useful for superficial injection site assessment

›Lung ultrasound

›Aspiration and pulmonary complication monitoring

›B-lines for pulmonary edema from aspiration

›Consolidation pattern in aspiration pneumonia

›Operator-dependent limitation

›Integrate with CXR findings

›Electrodiagnostic studies — critical diagnostic test

›Repetitive nerve stimulation (RNS)

›Low-frequency 2 to 3 Hz — decremental response possible

›High-frequency 50 Hz — incremental response (facilitation) most distinctive

›Single supramaximal nerve stimulation

›Small-amplitude CMAP in clinically affected muscles — most consistent finding

›Abnormality present even in mild cases

›Single-fiber EMG

›Increased jitter and blocking

›Most sensitive electrodiagnostic test especially in mild disease

›Post-exercise facilitation

›25% or greater increment in CMAP amplitude after brief maximal contraction

›Sensitivity 95%, specificity 100%

07Disposition/dispo28

Admission and level of care

›All suspected wound botulism requires ICU admission

›Respiratory failure can develop rapidly and unpredictably

›100% of patients in wound botulism outbreak required mechanical ventilation

›Baseline normal mentation does not predict safe floor-level monitoring

›ICU monitoring requirements

›Serial FVC and NIF every 4 to 6 hours

›Continuous pulse oximetry and telemetry

›Neurology and critical care co-management

Transfer criteria

›Transfer indications

›Facility without ICU capability — transfer to tertiary center immediately

›Do not delay antitoxin administration pending transfer

›Antitoxin can be administered at referring facility before transport

›Neuromuscular specialty center preferred for management

›Electrodiagnostic studies and serial monitoring

›Air transport for remote locations

›Pre-intubate if any respiratory concern before long transport

Public health and discharge planning

›Mandatory reporting

›State health department notification immediately

›Botulism is nationally notifiable under federal law

›Health department coordinates antitoxin release and cluster investigation

›Cluster investigation trigger — identify shared drug supply exposure

›Long-term recovery planning

›Recovery from wound botulism measured in weeks to months

›Nerve terminal regeneration is the rate-limiting step

›Long-term acute care or skilled nursing facility often required post-ICU

08Treatment/t87

Antitoxin administration

›Heptavalent botulinum antitoxin (BAT)

›Dosing

›Adults: one vial (approximately 52 mL) IV

›Administered as single IV infusion after dilution per package insert

›Timing and access

›Contact CDC Emergency Operations Center: 770-488-7100 — available 24 hours

›Do not delay for laboratory confirmation — treat on clinical suspicion

›Administration within 2 days of symptom onset associated with significantly better outcomes

›Hospital stay 5 days vs 15.5 days with later treatment

›ICU stay 4 days vs 12 days with later treatment

›Mechanical ventilation duration 6 days vs 14.5 days with later treatment

›Adverse effects and precautions

›Anaphylaxis risk approximately 1% to 2%

›Epinephrine at bedside during infusion

›Skin testing not recommended — delays treatment without meaningful risk reduction

›Prior equine serum exposure increases hypersensitivity risk

Antibiotic therapy

›Wound decontamination antibiotics

›Penicillin G IV

›3 to 4 million units IV every 4 hours

›Eradicates C. botulinum from wound — reduces ongoing toxin production

›Does not neutralize circulating toxin — antitoxin must be given separately

›Metronidazole IV — alternative when penicillin allergy

›500 mg IV every 8 hours

›Equivalent anaerobic coverage against C. botulinum

›Duration

›Minimum 10 to 14 days post-debridement

›Guided by wound clinical response

›Antibiotics to avoid — neuromuscular blockade potentiation

›Aminoglycosides — gentamicin, tobramycin, amikacin

›Potentiate presynaptic acetylcholine release blockade

›Can precipitate or worsen respiratory failure

›Magnesium sulfate

›Blocks calcium-mediated acetylcholine release

›Avoid in all forms of botulism

Surgical management

›Wound debridement and drainage

›Mandatory for all wound botulism cases

›Removes source of ongoing toxin production

›Anaerobic wound environment must be disrupted

›Abscess drainage

›Incision and drainage of all identified abscesses

›Send wound contents for anaerobic culture

›Debridement of devitalized tissue

›Remove necrotic or devitalized tissue at all injection sites

›Do not delay antitoxin pending surgical intervention

Respiratory management

›Mechanical ventilation

›Intubation thresholds

›FVC < 15 mL/kg — intubate

›NIF weaker than -20 cmH2O — intubate

›Clinical deterioration or inability to protect airway — intubate immediately

›RSI agent selection

›Avoid succinylcholine — unpredictable response at dysfunctional NMJ

›Rocuronium preferred if paralytic agent required

›Ventilator settings

›Standard lung-protective strategy

›Tidal volume 6 to 8 mL/kg ideal body weight

›Anticipate prolonged ventilatory support — weeks to months

›Ventilator weaning

›Serial FVC monitoring during recovery

›FVC > 15 mL/kg supports weaning trial

›NIF stronger than -30 cmH2O supports weaning trial

›Tracheostomy consideration for prolonged ventilation

›If intubation anticipated beyond 10 to 14 days

Supportive care

›Nutrition and gastrointestinal support

›NPO until airway secured

›Dysphagia and aspiration risk until bulbar function assessed

›NG or OG tube for enteral feeding after intubation

›Autonomic GI dysfunction management

›Gastroparesis and constipation from autonomic involvement

›Parenteral nutrition if enteral intolerance occurs

›Stool softeners and bowel regimen

›Urinary management

›Urinary retention from autonomic dysfunction

›Foley catheter insertion as needed

›Monitor urine output as volume status surrogate

›Venous thromboembolism prophylaxis

›Pharmacologic prophylaxis when not contraindicated

›Enoxaparin 40 mg SC once daily for standard DVT prophylaxis

›Dose adjust for renal impairment

›Mechanical prophylaxis — compression devices

›Apply in all immobile patients

›Physical and occupational therapy

›Early passive range of motion during ICU

›Prevent contractures during prolonged weakness

›Serial strength assessments to track recovery

›Progressive rehabilitation as strength returns

›Recovery timeline weeks to months

›Fatigue and weakness may persist up to one year

09Special Populations/sp48

Pregnancy

›Pregnancy-specific considerations

›Antitoxin administration

›BAT is the only available antitoxin — administer despite pregnancy given life-threatening nature

›Risk-benefit discussion with obstetrics team

›Limited data — fetal risk from toxin likely exceeds antitoxin risk

›Antibiotic safety

›Penicillin G — Category B, preferred first-line

›Metronidazole — Category B, acceptable in second and third trimester

›Avoid aminoglycosides — ototoxicity risk to fetus

›Respiratory management

›Maternal oxygenation target SpO2 95% or greater — fetal oxygen delivery

›Fetal monitoring when viable gestation

›Obstetric consultation for delivery planning if critical illness

›Wound management

›Surgical debridement performed with fetal monitoring

›Avoid prone positioning for wound access if possible in late pregnancy

Geriatric

›Older adult considerations

›Baseline respiratory reserve

›Reduced FVC and NIF at baseline — lower thresholds may trigger intubation sooner

›Pre-existing pulmonary disease worsens prognosis

›Cognitive assessment

›Baseline dementia may limit symptom reporting

›Delirium in ICU common with prolonged intubation

›Medication management

›Penicillin G — dose reduce for renal impairment

›CrCl 10 to 50 mL/min — reduce dose by 25% to 50%

10Background/b61

Epidemiology

›Incidence and distribution

›Wound botulism now accounts for the majority of adult botulism cases in the United States

›Historically rare — foodborne and infant botulism predominated

›Dramatic increase since 1990s driven by black tar heroin injection drug use

›Geographic distribution

›Western United States — California, Arizona, Texas border regions

›Increasing cases reported in Europe particularly United Kingdom and Germany

›Clusters follow black tar heroin supply routes

›Demographics

›Adults aged 20 to 50 years predominate — injection drug use population

›Traumatic wound botulism affects all ages — rare

›Mortality and morbidity

›Case fatality rate approximately 5% to 15% with appropriate treatment

›Higher before antitoxin era — historical mortality exceeded 60%

›Death typically from respiratory failure or aspiration pneumonia

›Morbidity

›Median ICU stay 30 to 60 days in severe cases

›Mechanical ventilation duration weeks to months

›Functional recovery incomplete in some patients at one year

Pathophysiology

›Toxin mechanism

›Clostridium botulinum produces botulinum neurotoxin (BoNT) — most potent biological toxin known

›Seven serotypes — A, B, C, D, E, F, G

›Types A and B most common in wound botulism

›Neuromuscular junction blockade

›BoNT binds presynaptic membrane of cholinergic nerve terminals

›Cleaves SNARE proteins — prevents acetylcholine vesicle fusion

›Blocks acetylcholine release into synaptic cleft — irreversible binding

›Consequence of presynaptic blockade

›Flaccid paralysis — motor end plates depolarize without ACh signal

›Autonomic cholinergic dysfunction — dry mouth, urinary retention, constipation

›Pupillary dilation — ciliary body and iris sphincter paralysis

›Wound colonization mechanism

›C. botulinum spores present in soil, heroin, or wound contamination

›Spores germinate in anaerobic, devitalized tissue — low redox potential required

›Skin popping creates deep subcutaneous pockets — ideal anaerobic environment

›In situ toxin production

›Vegetative C. botulinum produces and releases BoNT locally

›Toxin absorbed into systemic circulation — hematogenous spread to neuromuscular junctions

›Unlike foodborne botulism — no preformed toxin ingested

Therapeutic Considerations

›Antitoxin principles

›BAT mechanism — neutralizes circulating free toxin

›Does not reverse already-bound toxin — does not restore blocked NMJ

›Early administration prevents further NMJ blockade

›Recovery requires nerve terminal regeneration — weeks to months

›Evidence for early administration

›Administration within 2 days of symptom onset markedly improves outcomes

›Delay results in longer ICU stay, ventilation, and hospital admission

›Class I recommendation — administer as soon as clinical diagnosis made

›Wound management as treatment

›Surgical debridement is definitive source control

›Removes toxin-producing organism from wound

›Antibiotic therapy alone is insufficient without physical removal

›Anaerobic environment disruption prevents ongoing toxin production

›Recovery biology

›Blocked NMJ terminals regenerate through axonal sprouting

›New synaptic contacts form — months required

›BoNT dissociates from original terminal over time — function partially returns

›Functional recovery determinants

›Severity of initial toxin burden

›Speed of antitoxin administration

›Prevention of complications — aspiration pneumonia, DVT, pressure injuries

11Patient Discharge Instructions/pdi35

copy discharge instructions

›Wound botulism recovery home instructions

›You were diagnosed with wound botulism — a serious nerve toxin disease

›Recovery takes weeks to months after the toxin is cleared

›Muscle strength returns gradually as nerve endings grow back

›Activity

›Rest and limit activity to what your strength allows

›Do not drive until cleared by your doctor

›Physical therapy appointments are important for recovery

›Medications after discharge

›Take all prescribed antibiotics exactly as directed until finished

›Do not stop early even if feeling better

›Do not take any aminoglycoside antibiotics — gentamicin, tobramycin

›These medications can worsen nerve-muscle junction recovery

›Avoid magnesium-containing products

›Check antacids and laxatives for magnesium content

›Drug use and prevention

›Injection drug use caused this life-threatening illness

›Resources for substance use treatment are available

›Skin popping and muscle injection carry the highest risk

›If continuing to use drugs — do not skin pop or muscle inject

›Seek harm reduction services for clean injection supplies

›Warning signs to return to emergency department immediately

›New or worsening difficulty breathing

›Difficulty swallowing or choking on liquids

›New double vision or drooping eyelids

›New weakness in arms or legs

›Dizziness or fainting on standing

12References/r24

Guidelines and key sources

›Clinical guidelines

›Rao AK et al. Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021. MMWR Recommendations and Reports. 2021. PMID 33956777

›Primary US guidance for all botulism types including wound botulism

›Covers antitoxin administration, diagnostic approach, and public health reporting

›Arnon SS et al. Botulinum Toxin as a Biological Weapon — JAMA 2001. PMID unavailable via DOI

›Consensus management recommendations from expert panel

›Adalja AA, Toner E, Inglesby TV. Clinical Management of Potential Bioterrorism-Related Conditions. NEJM 2015

›Includes botulism management in bioterrorism context

›Epidemiology and outbreak reports

›Peak CM et al. Wound Botulism Outbreak Among Persons Who Use Black Tar Heroin, San Diego County 2017-2018. MMWR 2019. PMID 30605447

›Outbreak data — 100% mechanical ventilation rate in wound botulism series

›Shapiro RL, Hatheway C, Swerdlow DL. Botulism in the United States: A Clinical and Epidemiologic Review. Ann Intern Med 1998. PMID 9696731

›Sobel J. Botulism. Clin Infect Dis 2005. PMID 16163636

›Antitoxin evidence

›Yu PA et al. Safety and Improved Clinical Outcomes in Patients Treated With New Equine-Derived Heptavalent Botulinum Antitoxin. Clin Infect Dis 2017. PMID 29293928

›Richardson JS et al. Safety and Clinical Outcomes of Heptavalent Botulinum Antitoxin. Clin Infect Dis 2020. PMID 31209461

›Chalk CH et al. Medical Treatment for Botulism. Cochrane Database Syst Rev 2019

›Electrodiagnostic references

›Oh SJ. Botulism: Electrophysiological Studies. Ann Neurol 1977. PMID 214021

›Padua L et al. Neurophysiological Assessment in Botulism: Usefulness of Single-Fiber EMG. Muscle Nerve 1999. PMID 10487905

›Witoonpanich R et al. Electrodiagnosis of Botulism and Clinico-Electrophysiological Correlation. Clin Neurophysiol 2009. PMID 19410507

›Coding standards

›ICD-10 A05.1 — Botulism

›SNOMED CT — Wound botulism disorder concept

Evidence & Review

Evidence & Review